erythrocyte destruction

Page 1:

Introduction to Increased Destruction of Erythrocytes

  • Excessive Fragmentation (Intravascular) Hemolysis

  • Clinical Features

  • Laboratory Findings

  • Tests of Accelerated Red Blood Cell Destruction

  • Tests of Increased Erythropoiesis

  • Laboratory Tests to Identify Specific Hemolytic Processes

  • Differential Diagnosis

Classification

  • Hemolysis

  • Normal Macrophage-Mediated Hemolysis and Bilirubin Metabolism

  • Plasma Hemoglobin Salvage During Normal Fragmentation Hemolysis

  • Excessive Macrophage-Mediated (Extravascular) Hemolysis

Objectives

  • Define hemolysis and recognize its hallmark clinical findings.

  • Differentiate a hemolytic disorder from hemolytic anemia by definition and recognition of laboratory findings.

  • Discuss methods of classifying hemolytic anemias and apply the classification to an unfamiliar anemia.

  • Describe the processes of fragmentation (intravascular) and macrophage-mediated (extravascular) hemolysis, including sites of hemolysis, catabolic products, and time frame for the appearance of those products after hemolysis.

  • Describe protoporphyrin catabolism (bilirubin production), including metabolites and their sites of production and excretion.

  • Describe mechanisms that salvage hemoglobin and heme during fragmentation hemolysis.

  • Describe changes to bilirubin metabolism and iron salvage systems that occur when the rate of fragmentation or macrophage-mediated hemolysis increases.

  • Identify, explain the diagnostic value, and interpret the results of laboratory tests that indicate increased hemolysis and erythropoiesis.

  • Differentiate between hemolytic anemias and other causes of increased erythropoiesis given laboratory or clinical information.

  • Differentiate between hemolytic anemias and other causes of bilirubinemia given laboratory or clinical information.

  • Interchange conjugation terminology for bilirubin fractions with Van den Bergh reaction terminology.

  • Explain the principle of the Van den Bergh reaction to quantitate and fractionate bilirubin in body fluids.

Case Study

  • A 34-year-old woman admitted to the hospital for a vaginal hysterectomy.

  • Excessive menstrual bleeding.

  • Preoperative laboratory test results within reference intervals.

  • No excessive blood loss during or after surgery.

  • Recovery was uneventful except for some expected pain.

  • Three days after surgery, abdominal pain and "root beer"-colored urine.

  • CBC revealed a hemoglobin level of 5.8 g/dL.

  • Questions:

    • What process is indicated by the root beer-colored urine?

    • What laboratory tests can be used to differentiate the cause of the hemolysis?

    • Based on the patient's clinical presentation, predict the results expected for each test listed for question 2.

Page 2:

Classification

  • Many anemias have a hemolytic component.

  • Hemolysis alone does not cause anemia in certain conditions.

  • Anemias with a secondary hemolytic component.

  • Hemolysis is the primary feature in some anemias.

  • Classification:

    • Acute versus chronic

    • Inherited versus acquired

    • Intrinsic versus extrinsic

    • Intravascular versus extravascular

    • Fragmentation versus macrophage-mediated

  • Table 20.1 shows a noncomprehensive list of hemolytic anemias categorized in this way.

  • Focus on the mechanism of hemolysis, specifically fragmentation and macrophage-mediated hemolytic conditions.

  • Acute versus chronic hemolysis delineates the clinical presentation.

  • Chronic hemolysis may be punctuated over time with hemolytic crises that cause anemia.

  • Glucose-6-phosphate dehydrogenase deficiency is an example of chronic hemolysis.

  • Classification of Selected Hemolytic Anemias by Primary Cause and Type of Hemolysis:

    • Extrinsic defects

    • Intrinsic defects

    • Hereditary conditions

Page 3: Erythrocyte Disorders

  • Acute hemolytic events can occur due to antimalarial drugs

    • Compensation returns when the drug is withdrawn

  • Chronic conditions can result in severe anemia

    • Bone marrow cannot generate cells fast enough to compensate

  • Thalassemia major is an example of a condition with chronically low oxygen-carrying capacity

    • RBC production is brisk, but each cell has an inadequate complement of one type of globin chain

    • Functional hemoglobin production is decreased overall

  • Inherited hemolytic conditions, such as thalassemia, are passed to offspring by mutant genes

  • Acquired hemolytic disorders develop in individuals who acquire an agent or condition that lyses RBCs

    • Malaria is an example of an infectious disease causing hemolytic disorders

  • Hemolytic disorders can be intrinsic or extrinsic

    • Intrinsic defects are in the RBC itself, while extrinsic defects are caused by external agents

  • Intrinsic defects include abnormalities of the RBC membrane, enzymatic pathways, or the hemoglobin molecule

  • Extrinsic hemolytic conditions are caused by substances in plasma or conditions affecting the circulatory system

  • Most intrinsic defects are inherited, while most extrinsic ones are acquired

HEMOLYSIS Normal Macrophage-Mediated Hemolysis and Bilirubin Metabolism

  • Detection of hemolysis depends on the detection of RBC breakdown products, such as bilirubin

  • RBCs live approximately 120 days and undergo metabolic and chemical changes

  • Macrophages recognize these changes and phagocytize aged erythrocytes, leading to macrophage-mediated hemolysis

  • The spleen, bone marrow, liver, lymph nodes, and circulating monocytes are involved in this process

  • Majority of RBC degradation occurs inside macrophages

  • Hemoglobin is hydrolyzed into heme and globin, with globin further degraded into amino acids

  • Iron is released from heme and recycled to needy cells

  • Protoporphyrin component is catabolized and the products are processed in the liver

  • Bilirubin and urobilinogen are excretory products derived from the protoporphyrin component of heme

Introduction to Increased Destruction of Erythrocytes

Blood circulation in the liver

  • Blood enters the liver lobule at the periphery via a hepatic artery and portal vein

  • Blood from each vessel enters the sinusoids between rows of hepatocytes

  • Sinusoids have a loose structure, allowing blood to percolate through the lobule

  • Blood drains into progressively larger veins that leave the liver to enter the inferior vena cava

Bilirubin metabolism in the liver

  • Bilirubin formed in macrophages enters the liver sinusoid via the hepatic artery

  • In the liver sinusoid, bilirubin dissociates from albumin

  • Bilirubin is carried into the hepatocyte by organic anion transporter (OAT) proteins

  • Inside the hepatocyte, bilirubin is bound to glutathione S-transferase for transport to the endoplasmic reticulum

  • Unconjugated bilirubin is joined with glucuronic acid by UDP glucuronosyltransferase to form conjugated bilirubin

  • Conjugated bilirubin is excreted by hepatocytes into the canaliculi by multi-drug resistant protein 2 (MRP2)

  • Conjugated bilirubin continues down to the common bile duct and eventually into the intestines

Structure of the liver lobule

  • Small ducts called canaliculi run from the central vein outward between hepatocytes

  • Canaliculi receive bile excreted by hepatocytes and channel it toward the exterior of the lobule

  • Canaliculi join into larger bile ducts that collect the bile into the common bile duct

Normal Catabolism of Hemoglobin

  • Macrophages lyse ingested red blood cells (RBCs) and separate hemoglobin into globin chains and heme components

  • Amino acids from the globin chains are reused

  • Heme is degraded to iron and protoporphyrin

  • Iron is returned to the blood to be reused

  • Protoporphyrin is degraded to unconjugated bilirubin

Catabolism of Heme to Bilirubin

  • In cells containing heme oxygenase, iron is removed from heme and the protoporphyrin ring is opened up to form biliverdin

  • Biliverdin is converted to unconjugated bilirubin by biliverdin reductase

  • Unconjugated bilirubin is secreted into the blood and binds to albumin for transport to the liver

  • UGT1A1 adds glucuronic acid to form conjugated bilirubin when it enters the hepatocyte

Visualizing the Color Changes of Hemoglobin Degradation

  • The degradation of heme can be seen in bruises or in the sclera of the eye after a vascular bleed

  • Initially, extravasated but deoxygenated blood gives the injury a purple-red appearance

  • As hemoglobin is degraded, the color changes to a greenish hue due to biliverdin

  • Ultimately, the color becomes yellow due to bilirubin

Page 5: Erythrocyte Disorders

  • Hepatocytes conjugate bilirubin in the blood entering the sinus

    • They are not always able to export all of it into the bile duct

    • Conjugated bilirubin is exported into sinusoidal blood via MRP3

  • Conjugated bilirubin is absorbed by downstream hepatocytes

    • OATP1B1 protein in the sinusoidal membrane facilitates absorption

  • Absorbed, conjugated bilirubin can be exported into canaliculi by downstream hepatocytes

BOX 20.2 Laboratory Testing for Serum Bilirubin

  • Total serum bilirubin level is the sum of conjugated and unconjugated forms

  • Most of the total bilirubin is composed of the unconjugated form in transit from macrophages to the liver

  • Typical reference intervals:

    • Total serum bilirubin level: 0.5-1.0 mg/dL

    • Direct (conjugated) serum bilirubin level: 0-0.2 mg/dL

    • Indirect (unconjugated) serum bilirubin level: 0-0.8 mg/dL

  • Conjugated bilirubin reacts well in water-based spectrophotometric assay

  • Unconjugated bilirubin requires alcohol to promote solubility in water

  • Total bilirubin level is measured by adding a solubilizing reagent

  • Direct bilirubin is measured alone without the solubilizing agent

  • Indirect bilirubin level is calculated by subtracting the direct value from the total value

Figure 20.3 Normal Macrophage-Mediated Hemolysis

  • In a macrophage, hemoglobin is degraded to heme and unconjugated bilirubin

  • Unconjugated bilirubin binds to albumin for transport to the liver

  • Hepatocytes convert unconjugated bilirubin to conjugated bilirubin

  • Conjugated bilirubin leaves the liver in bile and enters the small intestine

  • Bacteria in the large intestine convert conjugated bilirubin to urobilinogen

  • Most urobilinogen is excreted in the stool, some is reabsorbed in the portal circulation

  • A small component of reabsorbed urobilinogen is filtered and excreted in the urine

Note: This transcript provides information about the metabolism and testing of bilirubin, as well as the normal process of macrophage-mediated hemolysis.

Page 6: Introduction to Increased Destruction of Erythrocytes

  • Conjugated bilirubin is oxidized by gut bacteria into urobilinogen

    • Urobilinogen is further oxidized to stercobilin and similar compounds that give stool its brown color

  • Some conjugated bilirubin and urobilinogen molecules are absorbed into the blood from the intestines

    • Absorbed by osmosis into the blood of the portal circulation

  • Bilirubin derivatives enter the liver via the portal veins and flow into the sinusoidal blood

    • Most of the conjugated bilirubin in the sinusoidal blood is absorbed into hepatocytes and recycled into bile

    • Urobilinogen is similarly recycled into bile

  • A small amount of direct bilirubin and urobilinogen remains in the blood entering the central vein

    • Filtered at the renal glomerulus and excreted in urine

  • Urobilin, a stool derivative of urobilinogen, gives urine its yellow color

Plasma Hemoglobin Salvage During Normal Fragmentation Hemolysis

  • Fragmentation hemolysis is the result of trauma to the RBC membrane, causing hemoglobin to spill into plasma

  • Approximately 10% to 20% of normal RBC destruction is via fragmentation

  • Hemoglobin is filtered through the glomerulus, leading to potential iron loss

  • Free hemoglobin and heme can scavenge nitric oxide and cause oxidative damage to cells

  • Haptoglobin-hemopexin-methemalbumin system salvages hemoglobin iron and prevents oxidation reactions

  • Hemoglobin binds to haptoglobin in plasma, avoiding filtration at the glomerulus and saving iron from urinary loss

  • Haptoglobin-hemoglobin complex is taken up by macrophages, where iron is salvaged and protoporphyrin is converted to unconjugated bilirubin

  • Hemopexin binds to free plasma hemoglobin, preventing oxidant injury to cells and tissues

  • Hemoglobinemia can lead to falsely elevated hemoglobin values in blood tests

  • Haptoglobin and hemopexin have therapeutic applications in reducing tissue damage during fragmentation hemolysis

Page 7: Erythrocyte Disorders

  • Unconjugated bilirubin is produced from the degradation of hemoglobin (Hb) and haptoglobin (Hpt) complex

  • The complex of hemoglobin-haptoglobin (Hb-Hpt) binds to CD163 on macrophages in various organs

  • The complex is internalized into the macrophage, releasing the hemoglobin dimer

  • The released hemoglobin dimer is degraded to heme, releasing iron and converting the protoporphyrin ring to unconjugated bilirubin

  • Haptoglobin is degraded

  • Unconjugated bilirubin is bound to albumin and processed through the liver

  • Free hemoglobin released into the blood with fragmentation forms methemoglobin

  • Hemopexin binds to free methemoglobin and forms a complex

  • The hemopexin-methemoglobin complex binds to CD91 on hepatocytes

  • The complex is internalized into the hepatocyte, releasing iron and converting the protoporphyrin ring to unconjugated bilirubin

  • Hemopexin is recycled to the blood

Figure 20.4 Normal Fragmentation Hemolysis

  1. A small number of red blood cells lyse within the circulation, forming schistocytes and releasing hemoglobin (Hb) into the blood, mostly as a/b dimers.

  2. Haptoglobin (Hpt) binds a hemoglobin dimer in a complex.

  3. The hemoglobin-haptoglobin complex binds to CD163 on the surface of macrophages in various organs.

  4. The complex is internalized into the macrophage, where the hemoglobin dimer is released.

  5. The hemoglobin dimer is degraded to heme, releasing iron and converting the protoporphyrin ring to unconjugated bilirubin.

  6. Haptoglobin is degraded.

  7. Unconjugated bilirubin released into the blood is bound to albumin and processed through the liver.

  8. Free hemoglobin released into the blood with fragmentation forms methemoglobin.

  9. Hemopexin binds free methemoglobin into a complex.

  10. The hemopexin-methemoglobin complex binds to CD91 on the surface of hepatocytes.

  11. The complex is internalized into the hepatocyte.

  12. Iron is released from the methemoglobin, and the protoporphyrin ring is converted to unconjugated bilirubin.

Note: Metheme can also bind to albumin, forming metheme-albumin, but this complex is temporary because metheme is rapidly transferred to hemopexin. (Adapted from Brunzel, N. A. [2013]. Fundamentals of Urine and Body Fluid Analysis. [3rd ed., p. 141, Figure 7-8]. St. Louis: Elsevier.)

Introduction to Increased Destruction of Erythrocytes

Hemopexin as a therapy for metheme toxicity (Page 8)

  • Hemopexin binds to ligand nonspecific CD91 receptor, LRP1, on hepatocytes

  • Hemopexin-metheme complex is internalized by endocytosis

  • Fate of internalized heme is still being researched

  • Hemopexin is recycled to blood from the hepatocyte

Metheme-albumin system for iron salvage (Page 8)

  • Albumin acts as a carrier for metheme in plasma

  • Metheme is rapidly transferred to hemopexin when available

  • Hemopexin-metheme complex travels to the liver for processing

Sequential and simultaneous salvage systems (Page 8)

  • Prevailing view: Haptoglobin binds hemoglobin, then hemopexin binds metheme, and then albumin binds metheme

  • Recent theories suggest these systems work simultaneously, especially during accelerated hemolysis

  • Hemopexin acts to prevent heme toxicity at all times

Renal handling of iron (Page 8)

  • Proximal tubular cells can reabsorb iron in various forms during excessive hemolysis

  • Iron staining of tubular cells in urinary sediment shows presence of hemosiderin

  • Small amount of filtered transferrin is salvaged by transferrin receptors on proximal tubular cells

  • Ferroportin on basolateral membrane of proximal tubular cells allows transfer of salvaged iron back into the blood

Excessive Macrophage-Mediated (Extravascular) Hemolysis

Increased macrophage-mediated hemolysis (Page 8)

  • Many hemolytic anemias result from increased macrophage-mediated hemolysis

  • Senescent RBCs and pathologic processes lead to expression of surface markers for removal by macrophages

  • If affected cells increase beyond normal senescence removal, anemia develops

Mechanisms of macrophage-mediated hemolysis (Page 8)

  • Excessive oxidation of hemoglobin leads to increased formation of Heinz bodies, which bind to RBC membrane and cause changes detected by macrophages

  • Intracellular parasites, complement, or immunoglobulins on RBC surface can also trigger macrophage-mediated hemolysis

  • Ingested RBCs are lysed within phagolysosomes in macrophages, contents are processed within the macrophage

Spherocytes and survival in circulation (Page 8)

  • Macrophage-mediated hemolysis often occurs in the spleen and liver, where macrophages possess receptors for senescent RBC markers

  • Macrophages may ingest a portion of the RBC membrane, leaving the remainder to reseal and form spherocytes

  • Spherocytes have shortened survival due to rigidity and inability to traverse the splenic sieve, may be fully ingested or mechanically lyse

Bilirubin levels in macrophage-mediated hemolytic anemias (Page 8)

  • Total plasma bilirubin level rises as RBCs are lysed prematurely

  • Increase in unconjugated bilirubin due to liver processing of increased load, producing more conjugated bilirubin

  • Increased urobilinogen forms in intestines, absorbed by portal circulation and excreted by kidney

  • Increased direct bilirubin absorbed into portal circulation but reprocessed through hepatocytes and into bile

  • Increased urobilinogen detectable in urine, unconjugated bilirubin bound to albumin and cannot pass through glomerulus

Role of hemopexin in macrophage-mediated hemolysis (Page 8)

  • Hemopexin may play an important role in preventing heme toxicity to macrophages when they ingest multiple erythrocytes

Page 9:

Main ideas:

  • Excess macrophage-mediated hemolysis

  • Laboratory findings indicating accelerated red blood cell destruction in fragmentation versus macrophage-mediated hemolysis

Supporting details:

  • More than the usual number of red blood cells are ingested each day by macrophages

  • Increased amount of unconjugated bilirubin is produced and released into the blood

  • Increased unconjugated bilirubin is presented to the liver, resulting in increased amount of conjugated bilirubin

  • Increased conjugated bilirubin in the intestine leads to increased urobilinogen formation and excretion in the stool

  • Increased urobilinogen in the intestine results in increased urobilinogen reabsorbed into the blood

  • Increased urobilinogen in the blood leads to increased urobilinogen filtered and excreted in the urine

  • Comparison of laboratory findings indicating accelerated red blood cell destruction in fragmentation versus macrophage-mediated hemolysis

Page 10:

Main ideas:

  • Excess fragmentation hemolysis: the role of macrophages

  • Excessive fragmentation (intravascular) hemolysis

  • Excess fragmentation hemolysis: the role of the liver

Supporting details:

  • Increased number of red blood cells lyse by fragmentation, releasing more hemoglobin into the blood

  • Haptoglobin binds the increased hemoglobin dimers, forming more complexes

  • Hemoglobin-haptoglobin complexes are taken up by macrophages bearing the CD163 receptor

  • Increased amount of hemoglobin dimers is released from the complexes, degraded to heme, and converted to unconjugated bilirubin

  • Unconjugated bilirubin is transported to the liver and processed as with excess macrophage-mediated hemolysis

  • Excessive fragmentation hemolysis is characterized by the appearance of hemoglobin in the plasma and the development of (met)hemoglobinemia

  • Iron salvage proteins form complexes with their respective ligands

  • Degradation of haptoglobin is accelerated compared to normal

  • If the amount of hemoglobin released from lysing red blood cells exceeds the capacity of haptoglobin, unbound free hemoglobin is rapidly oxidized, forming methemoglobin

  • Hemopexin binds to methemoglobin and is captured by the CD91 receptor on hepatocytes

  • The complex is internalized by the hepatocyte, iron is released, and the protoporphyrin ring is converted to unconjugated bilirubin

  • A small amount of hemopexin is recycled to the blood, while most is degraded

Page 12: Introduction to Increased Destruction of Erythrocytes

  • Unconjugated bilirubin is produced during heme degradation in the liver

    • Circulates in the blood

  • Conjugated bilirubin is produced in the liver and excreted in the urine and feces

    • Urobilinogen levels are increased in both urine and feces

    • Urine bilirubin levels are negative

  • Hemoglobinuria occurs when excess hemoglobin is reabsorbed into the circulation

  • Schistocytes are fragmented red blood cells

  • Excess hemolysis leads to hemoglobinuria

Page 13: Fate of Iron Removed from Salvaged Hemoglobin in the Kidney

  • Iron salvaged from absorbed hemoglobin can be transported into the circulation

    • Binds to transferrin for transport

  • Excess iron is stored as ferritin and some is converted to hemosiderin

  • Hemosiderin can be detected in urine sediment using the Prussian blue stain

  • Haptoglobin and hemopexin levels decrease when there are high levels of metheme

  • Hemoglobin and heme can appear in the urine (hemoglobinuria) if the salvage capacity of plasma proteins is exceeded

  • Iron-containing proteins are absorbed into proximal tubular cells

  • Proximal tubular cells possess receptors for reabsorption of iron-containing proteins

  • Proximal tubular cells can catabolize heme and salvage iron for export to the plasma

  • Bilirubin conjugation and disposition in proximal tubular cells is uncertain

  • Excess iron in proximal tubular cells is stored as ferritin and some is converted to hemosiderin

  • Hemosiderin can be detected in urine sediment using the Prussian blue stain

  • Elevated levels of plasma indirect bilirubin and urinary urobilinogen are measurable

  • Time course of findings assists with differential diagnosis

  • Rise in reticulocytes several days later would also be seen after an acute onset

Page 14: Introduction to Increased Destruction of Erythrocytes

Clinical Features

  • Hemolysis may be the primary cause of anemia

    • Symptoms: fatigue, dyspnea, dizziness

    • Signs: pallor, tachycardia

  • Increase in plasma bilirubin leads to yellow tinge in plasma and body tissues

    • Jaundice: yellow color of skin and sclera

    • Icterus: yellow plasma and tissues

  • Jaundice can occur in conditions other than hemolysis

  • Jaundice in hemolysis is called hemolytic jaundice or prehepatic jaundice

  • Unconjugated bilirubin can lead to brain damage in newborns (kernicterus)

  • Frequency or constancy of jaundice provides clues to the cause

  • Splenomegaly and gallstones can develop with chronic hemolysis

  • Bone deformities can occur in children with chronic hemolysis

  • Acute hemolysis can be confused with an acute infectious process

  • Acute fragmentation hemolysis can lead to renal failure

Laboratory Findings

  • Tests of Accelerated Red Blood Cell Destruction

    • Bilirubin: increased unconjugated bilirubin in hemolysis

    • Urine Hemoglobin and Urine Hemosiderin: indicative of fragmentation hemolysis

Page 15:

  • Elevated plasma glucose levels lead to an increase in glycated hemoglobin value.

    • Coexistence of hemolysis with diabetes leads to falsely lowered glycated hemoglobin values.

    • This is a recognized problem in the interpretation of glycated hemoglobin values for glucose control.

  • RBC survival assay using random labeling of blood with chromium-51 radioisotope is the reference method for RBC survival studies.

    • Blood is collected, mixed with the isotope, and returned to the patient.

    • The labeled cells reflect normal peripheral blood.

    • Disappearance of the label from the blood is measured over time.

  • Lactate dehydrogenase activity is often increased in patients with fragmentation hemolysis.

    • This is due to the release of the enzyme from ruptured RBCs.

    • Other conditions such as myocardial infarction or liver disease can also cause increases in lactate dehydrogenase.

  • Increased erythropoiesis is observed in hemolytic processes.

    • Hypoxia associated with hemolysis leads to increased erythropoiesis.

    • Laboratory findings indicating increased erythropoiesis include an increase in circulating reticulocytes and nucleated RBCs.

  • A complete blood count (CBC) can provide clues to the cause of hemolysis.

    • Hemoglobin, hematocrit, and number of RBCs reflect whether hemolysis has caused anemia.

    • Spherocytes are seen with macrophage-mediated hemolysis, while schistocytes are noted with fragmentation hemolysis.

  • Haptoglobin can be quantified to indicate fragmentation hemolysis.

    • A substantial decline in serum haptoglobin level indicates fragmentation hemolysis.

    • Low haptoglobin levels suggest hemolysis but may also be due to impaired synthesis caused by liver disease.

  • Hemopexin may demonstrate a low value in hemolysis.

    • Hemopexin assays may be more valuable for detection of hemopexin depletion in conditions such as sepsis.

  • Tests to determine the rate of endogenous carbon monoxide production have been developed.

    • Carbon monoxide is produced in the first step of heme breakdown by heme oxygenase.

    • Increased carbon monoxide production has been detected in some patients with hemolytic anemia.

  • Glycated hemoglobin levels can be used as an indicator of RBC survival.

    • Glycated hemoglobin increases over the life of a cell as it is exposed to plasma glucose.

    • The glycated hemoglobin level is usually decreased in chronic hemolytic disease.

    • There is significant variability in RBC lifespan among hematologically normal individuals, making the use of glycated hemoglobin for detection of hemolysis problematic without baseline values.

Page 16: Introduction to Increased Destruction of Erythrocytes

Complete Blood Count and Red Blood Cell Morphology

  • Peripheral blood film evaluation is crucial

    • Increase in poly-chromatic RBCs (reticulocytes) and nucleated RBCs represents bone marrow compensation for hemolysis or blood loss

    • Schistocytes are expected with excessive fragmentation hemolysis

    • Spherocytes may be seen with macrophage-mediated processes

    • Additional morphologic changes to RBCs may point toward the cause of the hemolysis

  • Increase in mean cell volume (MCV) is usually seen with extreme compensatory reticulocytosis resulting from larger, prematurely released "shift" reticulocytes

    • MCV may not increase to greater than the reference interval but rather may be more than the baseline value for that patient

    • Exceptions occur if the hemolytic condition itself involves smaller cells that counter the increased volume of the reticulocytes

  • Red cell distribution width (RDW) can be expected to rise with reticulocytosis

    • Addition of larger reticulocytes can be expected to extend the range of cell volumes

  • Leukocytosis and thrombocytosis may accompany acute hemolytic anemia

    • Considered reactions to the hemolytic process

    • Low platelet counts in association with other signs of hemolysis may indicate a platelet-consuming microangiopathic process

Reticulocyte Count

  • Most commonly used test to detect accelerated erythropoiesis

  • Expected to rise during hemolysis or hemorrhage

  • All measures of reticulocyte production should rise: absolute reticulocyte count, relative reticulocyte count, reticulocyte production index, and immature reticulocyte fraction

  • Association of reticulocytosis with hemolysis is strong

  • Exceptions occur during aplastic crises of some hemolytic anemias and in some immunohemolytic anemias with hypoplastic marrow

Bone Marrow Examination

  • Usually not necessary to diagnose hemolytic anemia

  • If conducted, bone marrow examination will reveal erythroid hyperplasia that results in peripheral blood reticulocytosis

  • Cellularity of bone marrow should be determined on a core biopsy specimen for a more accurate assessment

Laboratory Tests to Identify Specific Hemolytic Processes

  • Appearance of spherocytes or schistocytes on a peripheral blood film can point to a hemolytic cause for anemia

  • Other abnormalities found on the film may help reveal the specific disorder causing the hemolysis

  • Other tests for diagnosis of specific types of hemolytic anemia are discussed in subsequent chapters

RBC Morphology Hemolytic Disorders

  • Spherocytes: Hereditary spherocytosis, IgG-mediated immune hemolytic anemia, thermal injury to RBCs

  • Elliptocytes (ovalocytes): Hereditary elliptocytosis

  • Acanthocytes: Abetalipoproteinemia, severe liver disease (spur cell anemia)

  • Burr cells: Pyruvate kinase deficiency, uremia

  • Schistocytes: Microangiopathic hemolytic anemia, traumatic cardiac hemolytic anemia, IgM-mediated immune hemolytic anemia

  • Erythrophagocytosis: Damage to RBC surface, especially due to complement-fixing antibodies

  • RBC agglutination: Cold agglutinins, immunohemolytic disease

Hematologic Findings Indicating Accelerated Red Blood Cell Production

  • Increased absolute reticulocyte count, immature reticulocyte fraction, reticulocyte production index

  • Rising mean cell volume (compared with baseline)

  • Polychromasia, nucleated RBCs

(Table 20.3)

Page 17:

  • Differential diagnosis of hemolytic anemias incorporates several intersecting lines of deduction.

  • Rapid decrease in hemoglobin concentration can signal hemolysis when hemorrhage and hemodilution have been ruled out.

    • Jaundice and reticulocytosis provide additional confirmation of a hemolytic cause.

    • Elevated urinary urobilinogen level strengthens the conclusion.

  • RBC morphology and haptoglobin levels can assist in differentiating fragmentation from a macrophage-mediated cause.

  • In chronic hemolysis, persistence of hemoglobinemia, hemoglobinuria, decreased serum haptoglobin level, indirect bilirubinemia, and reticulocytosis can be expected.

  • Hemolytic anemias must be differentiated from other anemias associated with bilirubinemia, reticulocytosis, or both.

  • Anemia with reticulocytosis but without bilirubinemia is expected during recovery from hemorrhage not treated with transfusion or with effective treatment of deficiencies such as iron deficiency.

  • Anemia that results from hemorrhage into a body cavity is characterized by reticulocytosis during recovery and bilirubinemia as a result of catabolism of the hemoglobin in the hemorrhaged cells.

  • Anemias associated with ineffective erythropoiesis, such as megaloblastic anemia, are essentially hemolytic, with the cell death occurring in the bone marrow.

  • Bilirubinemia and elevated serum lactate dehydrogenase levels are to be expected, but the reticulocyte count is low.

  • Differential diagnosis may rely on negative results of tests for increased cell destruction or accelerated production.

Figure 20.7 Hemolysis Timelines:

  • Example of fragmentation (intravascular) hemolysis timeline.

    • Hemoglobin is detectable in plasma and urine for a period very soon after the hemolysis occurs.

    • Haptoglobin levels will drop as the plasma hemoglobin rises.

    • Protoporphyrin of salvaged hemoglobin will be processed to bilirubin that will rise after the hemolytic event.

    • Reticulocyte indices will also rise several days after the hemolytic event.

  • Example of macrophage-mediated (extravascular) hemolysis timeline.

    • Evidence of hemolysis is delayed until bilirubin and reticulocytes rise.

    • Contents of the red blood cells do not enter the blood.

TABLE 20.5 Differential Diagnosis of Hemolytic Anemias Versus Other Causes of Indirect Bilirubinemia and Reticulocytosis:

  • Differential diagnosis of hemolytic anemias versus other causes of indirect bilirubinemia and reticulocytosis.

  • Provides a comparison of hemolytic anemias with acute and chronic fragmentation and macrophage-mediated hemolysis, as well as acute hemorrhage.

Page 18: CHAPTER 20 Introduction to Increased Destruction of Erythrocytes

Review Questions:

  • The term hemolytic disorder in general refers to a disorder in which there is:

    • Increased destruction of RBCs in the blood, bone marrow, or spleen

    • Excessive loss of RBCs from the body

    • Inadequate RBC production by the bone marrow

    • Increased plasma volume with unchanged red cell mass

  • RBC destruction that occurs when macrophages ingest and destroy RBCs is termed:

    • Extracellular

    • Macrophage mediated

    • Intra-organ

    • Extrahematopoietic

  • A sign of hemolysis that is typically associated with both fragmentation and macrophage-mediated hemolysis is:

    • Hemoglobinuria

    • Hemosiderinuria

    • Hemoglobinemia

    • Elevated urinary urobilinogen level

Summary:

  • A hemolytic disorder is a condition in which there is increased destruction of red blood cells (RBCs) and a compensatory acceleration in RBC production by the bone marrow.

  • A hemolytic anemia develops when the bone marrow is unable to compensate for the shortened survival of the RBCs.

  • Hemolytic anemias can be classified as acute or chronic, intravascular or extravascular, acquired or inherited, intrinsic or extrinsic, and fragmentation or macrophage mediated.

  • Most RBC death in healthy individuals occurs via macrophages of the spleen and liver. A small amount occurs by fragmentation due to mechanical trauma.

  • Hemoglobin from RBCs is converted to heme and globin within macrophages. Heme is further degraded to iron, carbon monoxide, and unconjugated bilirubin. The bilirubin is secreted into the blood, where it binds to albumin and is transported to the liver. In the liver, bilirubin is conjugated with glucuronic acid and excreted as bile into the intestines, and it is converted to urobilinogen by intestinal bacteria. Some urobilinogen is reabsorbed into the portal circulation and reexcreted through the liver. A small amount of urobilinogen remains in the blood, and it is excreted by the kidney into the urine.

  • In macrophage-mediated (extravascular) hemolytic anemia, there is an increase in unconjugated bilirubin in the plasma and an increase in urobilinogen in the stool and urine. Spherocytes may be seen on the peripheral blood film.

  • Signs of fragmentation (intravascular) hemolysis include (met) hemoglobinemia, (met)hemoglobinuria, and hemosiderinuria. Serum haptoglobin is markedly decreased or absent. Schistocytes may be seen on the peripheral blood film.

  • Jaundice can result from increased serum unconjugated bilirubin during any hemolytic anemia.

  • Major clinical features of chronic inherited hemolytic anemia are varying degrees of anemia, jaundice, splenomegaly, and the development of cholelithiasis. In children, bone abnormalities may develop as a result of accelerated erythropoiesis.

  • Laboratory studies providing evidence of hemolytic anemia include tests for increased RBC destruction and compensatory increase in the rate of erythropoiesis. Elevated serum indirect bilirubin level with a normal serum direct bilirubin level suggests accelerated RBC destruction. A moderate to marked decrease in serum haptoglobin level suggests a fragmentation cause of hemolysis. The reticulocyte count is the most commonly used laboratory test to identify accelerated erythropoiesis, including an elevation of the immature reticulocyte fraction. Other tests that are specific to a particular diagnosis also may be needed.

  • Hemolytic anemias must be differentiated from other anemias with reticulocytosis, including the post-acute hemorrhage state and recovery from iron, vitamin B12, or folate deficiency, and from those with bilirubinemia, such as with internal bleeding.

Differential Diagnosis of Hemolytic Anemias Versus Other Causes of Indirect Bilirubinemia and Reticulocytosis:

  • Hemoglobin Level: Rapidly dropping

  • Indirect Bilirubinemia: Absent

  • Reticulocytosis: Absent

  • Spherocytes or Schistocytes: Absent

  • Hemodilution: Absent

  • Recovery from hemorrhage:

    • Hemoglobin Level: Rising

    • Indirect Bilirubinemia: Absent or declining

    • Reticulocytosis: Present

    • Spherocytes or Schistocytes: Absent

  • Treated anemia (iron, vitamin B12, or folate deficiency):

    • Hemoglobin Level: Rising

    • Indirect Bilirubinemia: Absent or declining

    • Reticulocytosis: Present

    • Spherocytes or Schistocytes: Absent

  • Hemorrhage into a body cavity:

    • Hemoglobin Level: Rapidly dropping

    • Indirect Bilirubinemia: Delayed

    • Reticulocytosis: Delayed

    • Spherocytes or Schistocytes: Absent

  • Ineffective erythropoiesis (e.g., megaloblastic anemia):

    • Hemoglobin Level: Dropping

    • Indirect Bilirubinemia: Persistent

    • Reticulocytosis: Absent

    • Spherocytes or Schistocytes: Absent

Note: The table continues on the next page.

Page 19:

  • An elderly white woman with worsening anemia

    • Decrease of approximately 0.5 mg/dL of hemoglobin each week

    • Pale skin and yellow eyes

    • Extreme fatigue and inability to complete daily tasks without napping

    • Tiredness on exertion

  • Tests for accelerated erythropoiesis

    • Urine urobilinogen level

    • Hemosiderin level

    • Reticulocyte count

    • Glycated hemoglobin level

  • A 5-year-old girl with darkening urine and mild anemia

    • Diagnosed with pneumonia and prescribed antibiotics

    • No history of anemia or family history of hematologic disorder

    • Mild anemia, polychromasia, and a few schistocytes

  • Personal and family history of mild hemolytic anemia

    • Elevated levels of total and indirect serum bilirubin

    • Elevated urinary urobilinogen

    • Decreased serum haptoglobin level

    • Elevated reticulocyte count and polychromasia on peripheral blood film

    • Spherocytes on peripheral blood film

  • Major fraction of bilirubin in plasma

    • Unconjugated bilirubin secreted by the liver

    • Urobilinogen reabsorbed from the intestines

    • Macrophage-secreted indirect bilirubin

    • Direct bilirubin conjugated by hepatocytes

  • Anemia worsening over several months

    • Decline in hemoglobin level

    • Polychromasia and anisocytosis on peripheral blood film

    • Elevated reticulocyte count and red cell distribution width (RDW)

    • Normal levels of total bilirubin, indirect fractions, and urinary urobilinogen

  • Test results expected with chronic fragmentation hemolysis

    • Increased serum haptoglobin

    • Positive Prussian Blue stain in urine sediment

References:

  1. Crosby, W. H., & Akeroyd, J. H. (1952). The limit of hemoglobin synthesis in hereditary hemolytic anemia. Am J Med, 13, 273–283.

  2. Hillman, R. S., & Henderson, P. A. (1969). Control of marrow production by the level of iron supply. J Clin Invest, 48(3), 454–460.

  3. Cui, Y., Konig, J., Leier, I., et al. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem, 276, 9626–9630.

  4. Keppler, D. (2014). The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Drug Metab Dispos, 42, 561–565.

  5. Sticova, E., & Jirsa, M. (2013). New insights in bilirubin metabolism and their clinical implications. World J Gastroent, 19(38), 6398–6407.

  6. Keppler, D., & Kartenbeck, J. (1996). The canalicular conjugate export pump encoded by the cmrp/cmoat gene. Prog Liver Dis, 14, 55–67.

  7. van de Steeg, E., Wagenaar, E., van der Kruijssen, C. M., et al. (2010). Organic anion transporting polypeptide 1a/1b-k